Related Experiment Video
Updated: Feb 6, 2026
Isolating Central Nervous System Tissues and Associated Meninges for the Downstream Analysis of Immune cells
Published on: May 19, 2020
Cryptococcal meningitis: the place of itraconazole
1Department of Clinical Research and Development, Janssen Research Foundation, Beerse, Belgium.
Abstract:
Itraconazole, an orally active broad-spectrum triazole antimycotic, has demonstrated anti-Cryptococcus activity in vitro and in animal models of cryptococcal meningitis. The drug has been used by a number of clinical groups for the treatment of cryptococcal meningitis, predominantly in AIDS patients. A problem that has been found with ketoconazole is the relatively low absorption of the drug in AIDS patients. This has resulted in ketoconazole plasma levels below the MIC90 (1-5 micrograms ml-1) needed to eliminate Cryptococcus neoformans. In addition, tissue levels of ketoconazole are lower than plasma levels. For itraconazole, the required MIC90 for Cr. neoformans is 0.1 microgram ml-1, and the plasma levels in AIDS patients receiving 200-400 mg daily, even in the case of reduced absorption, are well above this MIC90. The itraconazole levels in the brain and in the meninges are higher than the plasma levels. Consequently, itraconazole has been considered a valid candidate for studies in patients with cryptococcal meningitis. Various treatment modalities have been used: primary oral therapy alone or in combination with amphotericin B or 5-fluorocytosine (5-FC); maintenance oral therapy after initial treatment with amphotericin B (with or without 5-FC); and first-line intravenous treatment in severely ill patients. The results were evaluated in four different groups. When the drug was given as primary oral therapy without combination with amphotericin B or 5-FC, the results depended greatly on the dose administered and on the life expectancy of the patient at inclusion. In general, daily doses of 400 mg were better than 200-mg doses.(ABSTRACT TRUNCATED AT 250 WORDS)
Insights
Itraconazole shows promise for treating cryptococcal meningitis, especially in AIDS patients, due to better absorption and higher drug levels than ketoconazole. Doses of 400 mg daily appear more effective for primary oral therapy.
Area of Science:
- Mycology
- Pharmacology
- Infectious Diseases
Background:
- Cryptococcal meningitis is a serious infection, particularly in immunocompromised individuals.
- Ketoconazole has shown limited efficacy in AIDS patients due to poor absorption and low plasma levels.
- Itraconazole, a triazole antimycotic, exhibits potent in vitro and in vivo activity against Cryptococcus neoformans.
Purpose of the Study:
- To evaluate itraconazole as a treatment for cryptococcal meningitis.
- To compare itraconazole's pharmacokinetic profile with ketoconazole in AIDS patients.
- To assess the efficacy of various itraconazole treatment regimens.
Main Methods:
- In vitro and animal model studies of anti-Cryptococcus activity.
- Clinical use in AIDS patients with cryptococcal meningitis.
- Administration of itraconazole via oral and intravenous routes in different therapeutic strategies.
- Evaluation of treatment outcomes in four distinct patient groups.
Main Results:
- Itraconazole achieves plasma levels well above the minimum inhibitory concentration (MIC90) for Cr. neoformans in AIDS patients.
- Brain and meningeal itraconazole concentrations exceed plasma levels.
- Primary oral itraconazole therapy showed dose-dependent efficacy, with 400 mg daily being superior to 200 mg.
- Combination therapies and maintenance regimens were also explored.
Conclusions:
- Itraconazole is a viable candidate for cryptococcal meningitis treatment, offering improved pharmacokinetic properties over ketoconazole.
- Optimal dosing and combination strategies require further investigation.
- Itraconazole demonstrates potential for managing cryptococcal meningitis, particularly in challenging patient populations.
